Bristol Myers (NYSE: BMY) president nets stock from 10,079 RSU vesting

Rhea-AI Filing Summary

Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.

To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.

Insider Trade Summary

10,079 shares exercised/converted

Mixed 3 txns

Insider Hickey Benjamin

Role President, RayzeBio Org.

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	10,079	$0.00	--
Exercise	Common Stock, $0.10 par value	10,079	$0.00	--
Tax Withholding	Common Stock, $0.10 par value	3,810	$55.05	$210K

Holdings After Transaction: Restricted Stock Units — 10,079 shares (Direct); Common Stock, $0.10 par value — 18,868 shares (Direct)

Footnotes (1)

1. The restricted stock units vest annually in three equal installments beginning on February 1, 2025. Shares withheld for payment of taxes upon vesting of restricted stock units. Each restricted stock unit converts into one share of common stock upon vesting.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hickey Benjamin

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, RayzeBio Org.

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.10 par value	02/01/2026		M		10,079(1)	A	$0	18,868	D
Common Stock, $0.10 par value	02/01/2026		F		3,810(2)	D	$55.05	15,058	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	02/01/2026		M			10,079	(1)	02/01/2027	Common Stock, $0.10 par value	10,079	$0	10,079	D

Explanation of Responses:

1. The restricted stock units vest annually in three equal installments beginning on February 1, 2025.

2. Shares withheld for payment of taxes upon vesting of restricted stock units.

3. Each restricted stock unit converts into one share of common stock upon vesting.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Benjamin Hickey	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BMY executive Benjamin Hickey report?

Benjamin Hickey reported RSU vesting and related share withholding. On February 1, 2026, 10,079 restricted stock units vested into common shares, with 3,810 shares withheld at $55.05 each to cover taxes under Bristol Myers Squibb’s equity compensation plan.

How many Bristol Myers Squibb (BMY) RSUs vested for Benjamin Hickey?

10,079 restricted stock units vested for Hickey on February 1, 2026. Each RSU converted into one share of common stock at a $0 exercise price, reflecting scheduled vesting of prior equity awards rather than an open-market stock purchase.

Why were 3,810 BMY shares withheld in Benjamin Hickey’s Form 4 filing?

3,810 shares were withheld to pay taxes on RSU vesting. When 10,079 RSUs vested, Bristol Myers Squibb withheld 3,810 common shares at $55.05 per share to satisfy tax obligations, a common feature of stock-based compensation programs.

How many BMY shares does Benjamin Hickey own after this transaction?

Hickey directly owns 15,058 Bristol Myers Squibb common shares after the filing. This reflects the net balance following the vesting of 10,079 RSUs and the withholding of 3,810 shares for taxes on February 1, 2026.

What ongoing equity awards does BMY executive Benjamin Hickey still hold?

Hickey continues to hold 10,079 restricted stock units. These RSUs vest in three equal annual installments beginning February 1, 2025, with each unit converting into one share of Bristol Myers Squibb common stock upon vesting at a $0 exercise price.

Is Benjamin Hickey’s BMY Form 4 transaction an open-market stock sale?

No, the filing reflects RSU vesting and tax withholding, not an open-market sale. Shares were acquired at $0 upon vesting and a portion was withheld at $55.05 per share solely to cover tax obligations associated with the equity award.